查看购物车
  • Traditional Chinese
  • English
封面
市场调查报告书
商品编码
1706767

淀粉样变性治疗市场－全球产业分析、规模、份额、成长、趋势及预测（2025-2035）

Amyloidosis Therapeutics Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2025-2035
出版日期: | 出版商: Transparency Market Research | 英文 198 Pages | 商品交期: 2-10个工作天内

价格

淀粉样变性治疗市场 - 报告范围

TMR 关于全球淀粉样变性治疗市场的报告研究了过去和当前的成长趋势和机会，以获得 2025 年至 2035 年预测期内市场指标的宝贵见解。该报告提供了 2019 年至 2035 年期间全球淀粉样变性治疗市场的收入，以 2025 年为基准年，2035 年为预测年。该报告还提供了 2025 年至 2035 年全球淀粉样变性治疗市场的年复合成长率(CAGR%)。

该报告是经过广泛研究后编写的。初步研究涉及大部分研究工作，其中分析师对关键意见领袖、行业领导者和舆论製造者进行了访谈。二次研究涉及参考主要参与者的产品文献、年度报告、新闻稿和相关文件，以了解淀粉样变性治疗市场。

市场概况
2024 年的市场价值 27亿美元
2035年的市场价值 63亿美元
复合年增长率 8.2%

该报告深入探讨了全球淀粉样变性治疗市场的竞争格局。我们已经确定了在全球淀粉样变性治疗市场中运营的关键参与者，并根据各种属性对每个参与者进行了分析。公司概况、财务状况、最新发展和 SWOT 是本报告介绍的全球淀粉样变性治疗市场参与者的属性。

目录

第一章：前言

第二章：假设与研究方法

第三章：执行摘要：全球市场

第四章：市场概览

  • 介绍
  • 概述
  • 市场动态
  • 2020-2035年全球市场分析与预测

第五章：关键见解

  • 重要产业事件（合作伙伴关係、协作、合併、收购等）
  • 技术进步
  • 最终用户的关键购买指标
  • 波特五力分析
  • 大环境分析
  • 主要国家/地区监管情况
  • 定价趋势
  • 价值链分析
  • 各地区/全球报销情况
  • 重点品牌/产品分析

第六章：全球市场分析与预测：依药物类型

  • 介绍与定义
  • 主要发现/进展
  • 2020-2035年各类型市场价值预测
    • 单株抗体
    • 蛋白酶体抑制剂
    • 免疫调节剂
    • 皮质类固醇
    • 烷化剂
    • 转甲状腺素蛋白稳定剂
    • 其他的
  • 不同药物类型的市场吸引力

第七章：全球市场分析与预测：按适应症

  • 介绍与定义
  • 主要发现/进展
  • 2020 年至 2035 年各适应症市场价值预测
    • AL（原发性）淀粉样变性
    • AA（继发性）淀粉样变性
    • 家族性ATTR淀粉样变性
  • 市场吸引力（按适应症）

第八章：全球市场分析与预测：按配销通路

  • 介绍与定义
  • 主要发现/进展
  • 2020-2035年配销通路市场价值预测
    • 医院药房
    • 零售药局
    • 网路药局
  • 配销通路的市场吸引力

第九章：全球市场分析与预测：按地区

  • 主要发现
  • 各地区市场价值预测
    • 北美洲
    • 欧洲
    • 亚太地区
    • 拉丁美洲
    • 中东和非洲
  • 各国家/地区市场吸引力

第十章：北美市场分析与预测

  • 我们
  • 加拿大

第 11 章：欧洲市场分析与预测

  • 德国
  • 英国
  • 法国
  • 义大利
  • 西班牙
  • 欧洲其他地区

第十二章：亚太市场分析与预测

  • 中国
  • 日本
  • 印度
  • 韩国
  • 澳洲和纽西兰
  • 亚太其他地区

第十三章：拉丁美洲市场分析与预测

  • 巴西
  • 墨西哥
  • 拉丁美洲其他地区

第 14 章：中东和非洲市场分析与预测

  • 海湾合作委员会国家
  • 南非
  • 中东和非洲其他地区

第 15 章：竞争格局

  • 市场参与者 - 竞争矩阵（依公司层级和规模）
  • 各公司市占率分析（2024 年）
  • 公司简介
    • Pfizer Inc.
    • Johnson & Johnson Services, Inc.
    • GSK plc
    • Takeda Pharmaceutical Company Limited
    • Amgen Inc.
    • Bristol-Myers Squibb Company
    • Alnylam Pharmaceuticals, Inc.
    • AstraZeneca
    • BridgeBio Inc.
    • Ionis Pharmaceuticals
    • Attralus, Inc.
    • Eisai Co., Ltd.
    • Other Prominent Players
Product Code: TMRGL86469

Amyloidosis Therapeutics Market - Scope of Report

TMR's report on the global amyloidosis therapeutics market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2025 to 2035. The report provides revenue of the global amyloidosis therapeutics market for the period 2019-2035, considering 2025 as the base year and 2035 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global amyloidosis therapeutics market from 2025 to 2035.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the amyloidosis therapeutics market.

Market Snapshot
Market Value in 2024US$ 2.7 Bn
Market Value in 2035US$ 6.3 Bn
CAGR8.2%

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global amyloidosis therapeutics market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global amyloidosis therapeutics market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global amyloidosis therapeutics market.

The report delves into the competitive landscape of the global amyloidosis therapeutics market. Key players operating in the global amyloidosis therapeutics market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global amyloidosis therapeutics market profiled in this report.

Key Questions Answered in Global amyloidosis therapeutics Market Report:

  • What is the sales/revenue generated by amyloidosis therapeutics across all regions during the forecast period?
  • What are the opportunities in the global amyloidosis therapeutics market?
  • What are the major drivers, restraints, opportunities, and threats in the market?
  • Which regional market is set to expand at the fastest CAGR during the forecast period?
  • Which segment is expected to generate the highest revenue globally in 2035?
  • Which segment is projected to expand at the highest CAGR during the forecast period?
  • What are the market positions of different companies operating in the global market?

Amyloidosis Therapeutics Market - Research Objectives and Research Approach

The comprehensive report on the global amyloidosis therapeutics market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global amyloidosis therapeutics market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2035 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global amyloidosis therapeutics market.

Table of Contents

1. Preface

  • 1.1. Market Definition and Scope
  • 1.2. Market Segmentation
  • 1.3. Key Research Objectives
  • 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary : Global Amyloidosis Therapeutics Market

4. Market Overview

  • 4.1. Introduction
    • 4.1.1. Segment Definition
    • 4.1.2. Industry Evolution / Developments
  • 4.2. Overview
  • 4.3. Market Dynamics
    • 4.3.1. Drivers
    • 4.3.2. Restraints
    • 4.3.3. Opportunities
  • 4.4. Global Amyloidosis Therapeutics Market Analysis and Forecasts, 2020-2035
    • 4.4.1. Market Revenue Projections (US$ Bn)

5. Key Insights

  • 5.1. Key Industry Events (Partnerships, Collaborations, Mergers, Acquisitions, etc.)
  • 5.2. Technological Advancements
  • 5.3. Key Purchase Metrics for End-Users
  • 5.4. PORTER's Five Forces Analysis
  • 5.5. PESTLE Analysis
  • 5.6. Regulatory Scenario by Key Countries/Regions
  • 5.7. Pricing Trends
  • 5.8. Value Chain Analysis
  • 5.9. Reimbursement Scenario by Region/globally
  • 5.10. Key Brand/Product Analysis

6. Global Amyloidosis Therapeutics Market Analysis and Forecasts, By Drug Type

  • 6.1. Introduction & Definition
  • 6.2. Key Findings / Developments
  • 6.3. Market Value Forecast By Type, 2020-2035
    • 6.3.1. Monoclonal Antibodies
    • 6.3.2. Proteasome Inhibitors
    • 6.3.3. Immunomodulator
    • 6.3.4. Corticosteroids
    • 6.3.5. Alkylating Agents
    • 6.3.6. Transthyretin stabilizers
    • 6.3.7. Others
  • 6.4. Market Attractiveness By Drug Type

7. Global Amyloidosis Therapeutics Market Analysis and Forecasts, By Indication

  • 7.1. Introduction & Definition
  • 7.2. Key Findings / Developments
  • 7.3. Market Value Forecast By Indication, 2020-2035
    • 7.3.1. AL (Primary) Amyloidosis
    • 7.3.2. AA (Secondary) Amyloidosis
    • 7.3.3. Familial ATTR Amyloidosis
  • 7.4. Market Attractiveness By Indication

8. Global Amyloidosis Therapeutics Market Analysis and Forecasts, By Distribution Channel

  • 8.1. Introduction & Definition
  • 8.2. Key Findings / Developments
  • 8.3. Market Value Forecast By Distribution Channel, 2020-2035
    • 8.3.1. Hospital Pharmacies
    • 8.3.2. Retail Pharmacies
    • 8.3.3. Online Pharmacies
  • 8.4. Market Attractiveness By Distribution Channel

9. Global Amyloidosis Therapeutics Market Analysis and Forecasts, By Region

  • 9.1. Key Findings
  • 9.2. Market Value Forecast By Region
    • 9.2.1. North America
    • 9.2.2. Europe
    • 9.2.3. Asia Pacific
    • 9.2.4. Latin America
    • 9.2.5. Middle East & Africa
  • 9.3. Market Attractiveness By Country/Region

10. North America Amyloidosis Therapeutics Market Analysis and Forecast

  • 10.1. Introduction
    • 10.1.1. Key Findings
  • 10.2. Market Value Forecast By Drug Type, 2020-2035
    • 10.2.1. Monoclonal Antibodies
    • 10.2.2. Proteasome Inhibitors
    • 10.2.3. Immunomodulator
    • 10.2.4. Corticosteroids
    • 10.2.5. Alkylating Agents
    • 10.2.6. Transthyretin stabilizers
    • 10.2.7. Others
  • 10.3. Market Value Forecast By Indication, 2020-2035
    • 10.3.1. AL (Primary) Amyloidosis
    • 10.3.2. AA (Secondary) Amyloidosis
    • 10.3.3. Familial ATTR Amyloidosis
  • 10.4. Market Value Forecast By Distribution Channel, 2020-2035
    • 10.4.1. Hospital Pharmacies
    • 10.4.2. Retail Pharmacies
    • 10.4.3. Online Pharmacies
  • 10.5. Market Value Forecast By Country, 2020-2035
    • 10.5.1. U.S.
    • 10.5.2. Canada
  • 10.6. Market Attractiveness Analysis
    • 10.6.1. By Drug Type
    • 10.6.2. By Indication
    • 10.6.3. By Distribution Channel
    • 10.6.4. By Country

11. Europe Amyloidosis Therapeutics Market Analysis and Forecast

  • 11.1. Introduction
    • 11.1.1. Key Findings
  • 11.2. Market Value Forecast By Drug Type, 2020-2035
    • 11.2.1. Monoclonal Antibodies
    • 11.2.2. Proteasome Inhibitors
    • 11.2.3. Immunomodulator
    • 11.2.4. Corticosteroids
    • 11.2.5. Alkylating Agents
    • 11.2.6. Transthyretin stabilizers
    • 11.2.7. Others
  • 11.3. Market Value Forecast By Indication, 2020-2035
    • 11.3.1. AL (Primary) Amyloidosis
    • 11.3.2. AA (Secondary) Amyloidosis
    • 11.3.3. Familial ATTR Amyloidosis
  • 11.4. Market Value Forecast By Distribution Channel, 2020-2035
    • 11.4.1. Hospital Pharmacies
    • 11.4.2. Retail Pharmacies
    • 11.4.3. Online Pharmacies
  • 11.5. Market Value Forecast By Country/Sub-region, 2020-2035
    • 11.5.1. Germany
    • 11.5.2. UK
    • 11.5.3. France
    • 11.5.4. Italy
    • 11.5.5. Spain
    • 11.5.6. Rest of Europe
  • 11.6. Market Attractiveness Analysis
    • 11.6.1. By Drug Type
    • 11.6.2. By Indication
    • 11.6.3. By Distribution Channel
    • 11.6.4. By Country/Sub-region

12. Asia Pacific Amyloidosis Therapeutics Market Analysis and Forecast

  • 12.1. Introduction
    • 12.1.1. Key Findings
  • 12.2. Market Value Forecast By Drug Type, 2020-2035
    • 12.2.1. Monoclonal Antibodies
    • 12.2.2. Proteasome Inhibitors
    • 12.2.3. Immunomodulator
    • 12.2.4. Corticosteroids
    • 12.2.5. Alkylating Agents
    • 12.2.6. Transthyretin stabilizers
    • 12.2.7. Others
  • 12.3. Market Value Forecast By Indication, 2020-2035
    • 12.3.1. AL (Primary) Amyloidosis
    • 12.3.2. AA (Secondary) Amyloidosis
    • 12.3.3. Familial ATTR Amyloidosis
  • 12.4. Market Value Forecast By Distribution Channel, 2020-2035
    • 12.4.1. Hospital Pharmacies
    • 12.4.2. Retail Pharmacies
    • 12.4.3. Online Pharmacies
  • 12.5. Market Value Forecast By Country/Sub-region, 2020-2035
    • 12.5.1. China
    • 12.5.2. Japan
    • 12.5.3. India
    • 12.5.4. South Korea
    • 12.5.5. Australia & New Zealand
    • 12.5.6. Rest of Asia Pacific
  • 12.6. Market Attractiveness Analysis
    • 12.6.1. By Drug Type
    • 12.6.2. By Indication
    • 12.6.3. By Distribution Channel
    • 12.6.4. By Country/Sub-region

13. Latin America Amyloidosis Therapeutics Market Analysis and Forecast

  • 13.1. Introduction
    • 13.1.1. Key Findings
  • 13.2. Market Value Forecast By Drug Type, 2020-2035
    • 13.2.1. Monoclonal Antibodies
    • 13.2.2. Proteasome Inhibitors
    • 13.2.3. Immunomodulator
    • 13.2.4. Corticosteroids
    • 13.2.5. Alkylating Agents
    • 13.2.6. Transthyretin stabilizers
    • 13.2.7. Others
  • 13.3. Market Value Forecast By Indication, 2020-2035
    • 13.3.1. AL (Primary) Amyloidosis
    • 13.3.2. AA (Secondary) Amyloidosis
    • 13.3.3. Familial ATTR Amyloidosis
  • 13.4. Market Value Forecast By Distribution Channel, 2020-2035
    • 13.4.1. Hospital Pharmacies
    • 13.4.2. Retail Pharmacies
    • 13.4.3. Online Pharmacies
  • 13.5. Market Value Forecast By Country/Sub-region, 2020-2035
    • 13.5.1. Brazil
    • 13.5.2. Mexico
    • 13.5.3. Rest of Latin America
  • 13.6. Market Attractiveness Analysis
    • 13.6.1. By Drug Type
    • 13.6.2. By Indication
    • 13.6.3. By Distribution Channel
    • 13.6.4. By Country/Sub-region

14. Middle East & Africa Amyloidosis Therapeutics Market Analysis and Forecast

  • 14.1. Introduction
    • 14.1.1. Key Findings
  • 14.2. Market Value Forecast By Drug Type, 2020-2035
    • 14.2.1. Monoclonal Antibodies
    • 14.2.2. Proteasome Inhibitors
    • 14.2.3. Immunomodulator
    • 14.2.4. Corticosteroids
    • 14.2.5. Alkylating Agents
    • 14.2.6. Transthyretin stabilizers
    • 14.2.7. Others
  • 14.3. Market Value Forecast By Indication, 2020-2035
    • 14.3.1. AL (Primary) Amyloidosis
    • 14.3.2. AA (Secondary) Amyloidosis
    • 14.3.3. Familial ATTR Amyloidosis
  • 14.4. Market Value Forecast By Distribution Channel, 2020-2035
    • 14.4.1. Hospital Pharmacies
    • 14.4.2. Retail Pharmacies
    • 14.4.3. Online Pharmacies
  • 14.5. Market Value Forecast By Country/Sub-region, 2020-2035
    • 14.5.1. GCC Countries
    • 14.5.2. South Africa
    • 14.5.3. Rest of Middle East & Africa
  • 14.6. Market Attractiveness Analysis
    • 14.6.1. By Drug Type
    • 14.6.2. By Indication
    • 14.6.3. By Distribution Channel
    • 14.6.4. By Country/Sub-region

15. Competition Landscape

  • 15.1. Market Player - Competition Matrix (By Tier and Size of companies)
  • 15.2. Market Share Analysis By Company (2024)
  • 15.3. Company Profiles
    • 15.3.1. Pfizer Inc.
      • 15.3.1.1. Company Overview
      • 15.3.1.2. Financial Overview
      • 15.3.1.3. Financial Overview
      • 15.3.1.4. Business Strategies
      • 15.3.1.5. Recent Developments
    • 15.3.2. Johnson & Johnson Services, Inc.
      • 15.3.2.1. Company Overview
      • 15.3.2.2. Financial Overview
      • 15.3.2.3. Financial Overview
      • 15.3.2.4. Business Strategies
      • 15.3.2.5. Recent Developments
    • 15.3.3. GSK plc
      • 15.3.3.1. Company Overview
      • 15.3.3.2. Financial Overview
      • 15.3.3.3. Financial Overview
      • 15.3.3.4. Business Strategies
      • 15.3.3.5. Recent Developments
    • 15.3.4. Takeda Pharmaceutical Company Limited
      • 15.3.4.1. Company Overview
      • 15.3.4.2. Financial Overview
      • 15.3.4.3. Financial Overview
      • 15.3.4.4. Business Strategies
      • 15.3.4.5. Recent Developments
    • 15.3.5. Amgen Inc.
      • 15.3.5.1. Company Overview
      • 15.3.5.2. Financial Overview
      • 15.3.5.3. Financial Overview
      • 15.3.5.4. Business Strategies
      • 15.3.5.5. Recent Developments
    • 15.3.6. Bristol-Myers Squibb Company
      • 15.3.6.1. Company Overview
      • 15.3.6.2. Financial Overview
      • 15.3.6.3. Financial Overview
      • 15.3.6.4. Business Strategies
      • 15.3.6.5. Recent Developments
    • 15.3.7. Alnylam Pharmaceuticals, Inc.
      • 15.3.7.1. Company Overview
      • 15.3.7.2. Financial Overview
      • 15.3.7.3. Financial Overview
      • 15.3.7.4. Business Strategies
      • 15.3.7.5. Recent Developments
    • 15.3.8. AstraZeneca
      • 15.3.8.1. Company Overview
      • 15.3.8.2. Financial Overview
      • 15.3.8.3. Financial Overview
      • 15.3.8.4. Business Strategies
      • 15.3.8.5. Recent Developments
    • 15.3.9. BridgeBio Inc.
      • 15.3.9.1. Company Overview
      • 15.3.9.2. Financial Overview
      • 15.3.9.3. Financial Overview
      • 15.3.9.4. Business Strategies
      • 15.3.9.5. Recent Developments
    • 15.3.10. Ionis Pharmaceuticals
      • 15.3.10.1. Company Overview
      • 15.3.10.2. Financial Overview
      • 15.3.10.3. Financial Overview
      • 15.3.10.4. Business Strategies
      • 15.3.10.5. Recent Developments
    • 15.3.11. Attralus, Inc.
      • 15.3.11.1. Company Overview
      • 15.3.11.2. Financial Overview
      • 15.3.11.3. Financial Overview
      • 15.3.11.4. Business Strategies
      • 15.3.11.5. Recent Developments
    • 15.3.12. Eisai Co., Ltd.
      • 15.3.12.1. Company Overview
      • 15.3.12.2. Financial Overview
      • 15.3.12.3. Financial Overview
      • 15.3.12.4. Business Strategies
      • 15.3.12.5. Recent Developments
    • 15.3.13. Other Prominent Players
      • 15.3.13.1. Company Overview
      • 15.3.13.2. Financial Overview
      • 15.3.13.3. Financial Overview
      • 15.3.13.4. Business Strategies
      • 15.3.13.5. Recent Developments

Amyloidosis Therapeutics Market

Amyloidosis Treatment Industry

Rare Disease Drug Market

Monoclonal Antibodies for Amyloidosis

ATTR Amyloidosis Treatment

Immunotherapy for Amyloidosis

Amyloidosis Drug Pipeline

Novel Therapies for Amyloidosis

Amyloidosis Research & Development

Amyloidosis Diagnosis & Treatment

Pharmaceutical Market for Amyloidosis

Amyloidosis Clinical Trials

Targeted Therapy for Amyloidosis

Amyloidosis Market Growth 2035

Emerging Treatments for Amyloidosis

Gene Therapy for Amyloidosis

Systemic Amyloidosis Drugs

List of Tables

  • Table 01: Global Amyloidosis Therapeutics Market Value (US$ Bn) Forecast, By Drug Type, 2020-2035
  • Table 02: Global Amyloidosis Therapeutics Market Value (US$ Bn) Forecast, By Indication, 2020-2035
  • Table 03: Global Amyloidosis Therapeutics Market Value (US$ Bn) Forecast, By Distribution Channel, 2020-2035
  • Table 04: Global Amyloidosis Therapeutics Market Value (US$ Bn) Forecast, By Region, 2020-2035
  • Table 05: North America - Amyloidosis Therapeutics Market Value (US$ Bn) Forecast, by Country, 2020-2035
  • Table 06: North America - Amyloidosis Therapeutics Market Value (US$ Bn) Forecast, by Drug Type, 2020-2035
  • Table 07: North America - Amyloidosis Therapeutics Market Value (US$ Bn) Forecast, By Indication, 2020-2035
  • Table 08: North America - Amyloidosis Therapeutics Market Value (US$ Bn) Forecast, By Distribution Channel, 2020-2035
  • Table 09: Europe - Amyloidosis Therapeutics Market Value (US$ Bn) Forecast, by Country, 2020-2035
  • Table 10: Europe - Amyloidosis Therapeutics Market Value (US$ Bn) Forecast, by Drug Type, 2020-2035
  • Table 11: Europe - Amyloidosis Therapeutics Market Value (US$ Bn) Forecast, By Indication, 2020-2035
  • Table 12: Europe - Amyloidosis Therapeutics Market Value (US$ Bn) Forecast, By Distribution Channel, 2020-2035
  • Table 13: Asia Pacific - Amyloidosis Therapeutics Market Value (US$ Bn) Forecast, by Country, 2020-2035
  • Table 14: Asia Pacific - Amyloidosis Therapeutics Market Value (US$ Bn) Forecast, by Drug Type, 2020-2035
  • Table 15: Asia Pacific - Amyloidosis Therapeutics Market Value (US$ Bn) Forecast, By Indication, 2020-2035
  • Table 16: Asia Pacific - Amyloidosis Therapeutics Market Value (US$ Bn) Forecast, By Distribution Channel, 2020-2035
  • Table 17: Latin America - Amyloidosis Therapeutics Market Value (US$ Bn) Forecast, by Country, 2020-2035
  • Table 18: Latin America - Amyloidosis Therapeutics Market Value (US$ Bn) Forecast, by Drug Type, 2020-2035
  • Table 19: Latin America - Amyloidosis Therapeutics Market Value (US$ Bn) Forecast, By Indication, 2020-2035
  • Table 20: Latin America - Amyloidosis Therapeutics Market Value (US$ Bn) Forecast, By Distribution Channel, 2020-2035
  • Table 21: Middle East & Africa - Amyloidosis Therapeutics Market Value (US$ Bn) Forecast, by Country, 2020-2035
  • Table 22: Middle East & Africa - Amyloidosis Therapeutics Market Value (US$ Bn) Forecast, by Drug Type, 2020-2035
  • Table 23: Middle East & Africa - Amyloidosis Therapeutics Market Value (US$ Bn) Forecast, By Indication, 2020-2035
  • Table 24: Middle East & Africa - Amyloidosis Therapeutics Market Value (US$ Bn) Forecast, By Distribution Channel, 2020-2035

List of Figures

  • Figure 01: Global Amyloidosis Therapeutics Market Value (US$ Bn) Forecast, by Region, 2025-2035
  • Figure 02: Global Amyloidosis Therapeutics Market Value Share Analysis, By Drug Type, 2024 and 2035
  • Figure 03: Global Amyloidosis Therapeutics Market Attractiveness Analysis, By Drug Type, 2025-2035
  • Figure 04: Global Amyloidosis Therapeutics Market Revenue (US$ Bn), by Monoclonal Antibodies, 2020-2035
  • Figure 05: Global Amyloidosis Therapeutics Market Revenue (US$ Bn), by Proteasome Inhibitors, 2020-2035
  • Figure 06: Global Amyloidosis Therapeutics Market Revenue (US$ Bn), by Immunomodulator, 2020-2035
  • Figure 07: Global Amyloidosis Therapeutics Market Revenue (US$ Bn), by Corticosteroids, 2020-2035
  • Figure 08: Global Amyloidosis Therapeutics Market Revenue (US$ Bn), by Alkylating Agents, 2020-2035
  • Figure 09: Global Amyloidosis Therapeutics Market Revenue (US$ Bn), by Transthyretin stabilizers, 2020-2035
  • Figure 10: Global Amyloidosis Therapeutics Market Revenue (US$ Bn), by Others, 2020-2035
  • Figure 11: Global Amyloidosis Therapeutics Market Value Share Analysis, By Indication, 2024 and 2035
  • Figure 12: Global Amyloidosis Therapeutics Market Attractiveness Analysis, By Indication, 2025-2035
  • Figure 13: Global Amyloidosis Therapeutics Market Revenue (US$ Bn), by AL (Primary) Amyloidosis, 2020-2035
  • Figure 14: Global Amyloidosis Therapeutics Market Revenue (US$ Bn), by AA (Secondary) Amyloidosis, 2020-2035
  • Figure 15: Global Amyloidosis Therapeutics Market Revenue (US$ Bn), by Familial ATTR Amyloidosis, 2020-2035
  • Figure 16: Global Amyloidosis Therapeutics Market Value Share Analysis, By Distribution Channel, 2024 and 2035
  • Figure 17: Global Amyloidosis Therapeutics Market Attractiveness Analysis, By Distribution Channel, 2025-2035
  • Figure 18: Global Amyloidosis Therapeutics Market Revenue (US$ Bn), by Hospital Pharmacies, 2020-2035
  • Figure 19: Global Amyloidosis Therapeutics Market Revenue (US$ Bn), by Retail Pharmacies, 2020-2035
  • Figure 20: Global Amyloidosis Therapeutics Market Revenue (US$ Bn), by Online Pharmacies, 2020-2035
  • Figure 21: Global Amyloidosis Therapeutics Market Value Share Analysis, By Region, 2024 and 2035
  • Figure 22: Global Amyloidosis Therapeutics Market Attractiveness Analysis, By Region, 2025-2035
  • Figure 23: North America - Amyloidosis Therapeutics Market Value (US$ Bn) Forecast, 2020-2035
  • Figure 24: North America - Amyloidosis Therapeutics Market Value Share Analysis, by Country, 2024 and 2035
  • Figure 25: North America - Amyloidosis Therapeutics Market Attractiveness Analysis, by Country, 2025-2035
  • Figure 26: North America Amyloidosis Therapeutics Market Value Share Analysis, By Drug Type, 2024 and 2035
  • Figure 27: North America Amyloidosis Therapeutics Market Attractiveness Analysis, By Drug Type, 2025-2035
  • Figure 28: North America - Amyloidosis Therapeutics Market Value Share Analysis, By Indication, 2024 and 2035
  • Figure 29: North America - Amyloidosis Therapeutics Market Attractiveness Analysis, By Indication, 2025-2035
  • Figure 30: North America - Amyloidosis Therapeutics Market Value Share Analysis, By Distribution Channel, 2024 and 2035
  • Figure 31: North America - Amyloidosis Therapeutics Market Attractiveness Analysis, By Distribution Channel, 2025-2035
  • Figure 32: Europe - Amyloidosis Therapeutics Market Value (US$ Bn) Forecast, 2020-2035
  • Figure 33: Europe - Amyloidosis Therapeutics Market Value Share Analysis, by Country, 2024 and 2035
  • Figure 34: Europe - Amyloidosis Therapeutics Market Attractiveness Analysis, by Country, 2025-2035
  • Figure 35: Europe Amyloidosis Therapeutics Market Value Share Analysis, By Drug Type, 2024 and 2035
  • Figure 36: Europe Amyloidosis Therapeutics Market Attractiveness Analysis, By Drug Type, 2025-2035
  • Figure 37: Europe - Amyloidosis Therapeutics Market Value Share Analysis, By Indication, 2024 and 2035
  • Figure 38: Europe - Amyloidosis Therapeutics Market Attractiveness Analysis, By Indication, 2025-2035
  • Figure 39: Europe - Amyloidosis Therapeutics Market Value Share Analysis, By Distribution Channel, 2024 and 2035
  • Figure 40: Europe - Amyloidosis Therapeutics Market Attractiveness Analysis, By Distribution Channel, 2025-2035
  • Figure 41: Asia Pacific - Amyloidosis Therapeutics Market Value (US$ Bn) Forecast, 2020-2035
  • Figure 42: Asia Pacific - Amyloidosis Therapeutics Market Value Share Analysis, by Country, 2024 and 2035
  • Figure 43: Asia Pacific - Amyloidosis Therapeutics Market Attractiveness Analysis, by Country, 2025-2035
  • Figure 44: Asia Pacific Amyloidosis Therapeutics Market Value Share Analysis, By Drug Type, 2024 and 2035
  • Figure 45: Asia Pacific Amyloidosis Therapeutics Market Attractiveness Analysis, By Drug Type, 2025-2035
  • Figure 46: Asia Pacific - Amyloidosis Therapeutics Market Value Share Analysis, By Indication, 2024 and 2035
  • Figure 47: Asia Pacific - Amyloidosis Therapeutics Market Attractiveness Analysis, By Indication, 2025-2035
  • Figure 48: Asia Pacific - Amyloidosis Therapeutics Market Value Share Analysis, By Distribution Channel, 2024 and 2035
  • Figure 49: Asia Pacific - Amyloidosis Therapeutics Market Attractiveness Analysis, By Distribution Channel, 2025-2035
  • Figure 50: Latin America - Amyloidosis Therapeutics Market Value (US$ Bn) Forecast, 2020-2035
  • Figure 51: Latin America - Amyloidosis Therapeutics Market Value Share Analysis, by Country, 2024 and 2035
  • Figure 52: Latin America - Amyloidosis Therapeutics Market Attractiveness Analysis, by Country, 2025-2035
  • Figure 53: Latin America Amyloidosis Therapeutics Market Value Share Analysis, By Drug Type, 2024 and 2035
  • Figure 54: Latin America Amyloidosis Therapeutics Market Attractiveness Analysis, By Drug Type, 2025-2035
  • Figure 55: Latin America - Amyloidosis Therapeutics Market Value Share Analysis, By Indication, 2024 and 2035
  • Figure 56: Latin America - Amyloidosis Therapeutics Market Attractiveness Analysis, By Indication, 2025-2035
  • Figure 57: Latin America - Amyloidosis Therapeutics Market Value Share Analysis, By Distribution Channel, 2024 and 2035
  • Figure 58: Latin America - Amyloidosis Therapeutics Market Attractiveness Analysis, By Distribution Channel, 2025-2035
  • Figure 59: Middle East & Africa - Amyloidosis Therapeutics Market Value (US$ Bn) Forecast, 2020-2035
  • Figure 60: Middle East & Africa - Amyloidosis Therapeutics Market Value Share Analysis, by Country, 2024 and 2035
  • Figure 61: Middle East & Africa - Amyloidosis Therapeutics Market Attractiveness Analysis, by Country, 2025-2035
  • Figure 62: Middle East & Africa Amyloidosis Therapeutics Market Value Share Analysis, By Drug Type, 2024 and 2035
  • Figure 63: Middle East & Africa Amyloidosis Therapeutics Market Attractiveness Analysis, By Drug Type, 2025-2035
  • Figure 64: Middle East & Africa - Amyloidosis Therapeutics Market Value Share Analysis, By Indication, 2024 and 2035
  • Figure 65: Middle East & Africa - Amyloidosis Therapeutics Market Attractiveness Analysis, By Indication, 2025-2035
  • Figure 66: Middle East & Africa - Amyloidosis Therapeutics Market Value Share Analysis, By Distribution Channel, 2024 and 2035
  • Figure 67: Middle East & Africa - Amyloidosis Therapeutics Market Attractiveness Analysis, By Distribution Channel, 2025-2035